XVXabier Villanueva

Xabier Villanueva

*This is an algorithmically generated author record based on publicly available information.

Xabier Villanueva has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Hans P. Steenackers

    Centre of Microbial and Plant Genetics (CMPG), Department of Microbial and Molecular Systems, KU Leuven

    2 shared publications
  • Christopher McGuigan

    School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 3NB, UK

    1 shared publication
  • Claudia Crestini

    CSGI - Center for Colloid and Surface Science, Via della Lastruccia 3

    1 shared publication
  • David De Coster

    Centre of Microbial and Plant Genetics, Kasteelpark Arenberg 20, bus 2460, B-3001 Leuven, Belgium

    1 shared publication
  • Dirk Daelemans

    KU Leuven Department of Microbiology, Immunology and Transplantation, Molecular Genetics and Therapeutics in Virology and Oncology Research Group, Rega Institute, Leuven Cancer Institute, Herestraat 49, Leuven, 3000, Belgium

    1 shared publication
  • Elisa Pileggi

    School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 3NB, UK

    1 shared publication

Latest Publications

  • Open Access

    Effect of chemical modifications of tannins on their antibiofilm effect against Gram-negative and Gram-positive bacteria

    by Xabier Villanueva, Lili Zhen, José Nunez Ares, Thijs Vackier, Heiko Lange, Claudia Crestini, Hans Steenackers

    (1) Background: Tannins have demonstrated antibacterial and antibiofilm activity, but the mechanisms of action are not completely elucidated. We are interested in understanding how to modulate the antibiofilm activity of tannins and in delineating the relationship between chemical determinants and antibiofilm activity. (2) Materials and methods: the effect of five different naturally acquired tannins and their chemical derivatives on biofilm formation and planktonic growth of Salmonella Typhimurium, Pseudomonas aeruginosa, Escherichia coli and Staphylococcus aureus was determined in the Calgary biofilm device. (3) Results: most of the unmodified tannins exhibited specific antibiofilm activity against the assayed bacteria. The chemical modifications were found to alter the antibiofilm activity level and spectrum of the tannins, with the positive charge introducing C 3 NMe 3 Cl-0.5 derivatization shifting the anti-biofilm spectrum towards Gram-negative bacteria and C 3 NMe 3 Cl-0.1 and the acidifying CH 3 COOH derivatization shifting the spectrum towards Gram-positive bacteria. Also, the quantity of phenolic-OH groups per molecule has a weak impact on the anti-biofilm activity of the tannins. (4) Conclusions: we were able to modulate the antibiofilm activity of several tannins by specific chemical modifications, providing a first approach for fine tuning of their activity and spectrum.

  • Open Access

    Drug repurposing: phosphate prodrugs of anticancer and antiviral FDA-approved nucleosides as novel antimicrobials

    by Fabrizio Pertusati, Elisa Pileggi, Jennifer Richards, Mandy Wootton, Thijs Van Leemputte, Leentje Persoons, David De Coster, Xabier Villanueva, Dirk Daelemans, Hans Steenackers, et al.

    Following a drug repurposing approach, we aimed to investigate and compare the antibacterial and antibiofilm activities of different classes of phosphate prodrugs (HepDirect, cycloSal, SATE and mix SATE) of antiviral and anticancer FDA-approved nucleoside drugs [zidovudine (AZT), floxouridine (FUDR) and gemcitabine (GEM)] against a variety of pathogenic Gram-positive and -negative bacteria. Ten prodrugs were synthesized and screened for antibacterial activity against seven Gram-negative and two Gram-positive isolates fully susceptible to traditional antibiotics, alongside six Gram-negative and five Gram-positive isolates with resistance mechanisms. Their ability to prevent and eradicate biofilms of different bacterial pathogens in relation to planktonic growth inhibition was also evaluated, together with their effect on proliferation, viability and apoptosis of different eukaryotic cells. The prodrugs showed decreased antibacterial activity compared with the parent nucleosides. cycloSal-GEM-monophosphate (MP) prodrugs 20a and 20b were the most active agents against Gram-positive bacteria (Enterococcus faecalis and Staphylococcus aureus) and retained their activity against antibiotic-resistant isolates. cycloSal-FUDR-MP 21a partially retained good activity against the Gram-positive bacteria E. faecalis, Enterococcus faecium and S. aureus. Most of the prodrugs tested displayed very potent preventive antibiofilm specific activity, but not curative. In terms of cytotoxicity, AZT prodrugs did not affect apoptosis or cell viability at the highest concentration tested, and only weak effects on apoptosis and/or cell viability were observed for GEM and FUDR prodrugs. Among the different prodrug approaches, the cycloSal prodrugs appeared the most effective. In particular, cycloSal (17a) and mix SATE (26) AZT prodrugs combine the lowest cytotoxicity with high and broad antibacterial and antibiofilm activity against Gram-negative bacteria.